About Leuko
Improving quality of life and outcomes for chemotherapy patients and others at risk of severe neutropenia, through the first noninvasive white cell monitor.
This is an investigational device. It is not for sale. The claims made on this website have not been evaluated by the FDA or the CE Mark authorities.
Executive Team
Carlos Castro Gonzalez
Chief Executive Officer
Developed prior licensed technologies for medical devices. Track record raising non-dilutive funds
Ian Butterworth
Chief Technology Officer
Measurement systems expert. Developed hardware and software for four prior medical device start-ups
Aurelien Bourquard
Chief Data Scientist
Designed cutting-edge AI and computer vision methods for biomedical imaging
Alvaro Sanchez-Ferro
Chief Medical Officer
Led numerous human studies for clinical validation of new technologies
Product Development
Alberto Pablo Trinidad
Senior Data Scientist
William Sprecher
Director of Manufacturing
Ganimete Lamaj Human Factors Engineer
Jose Antonio Pelaez Escobar Machine Learning Engineer
Ryan Benasutti Product Software Engineer
Board of Directors
Amy Salzhauer
Partner at Good Growth Capital
Marta Gaia Zanchi
Founder at Nina Capital
Paul Hartung
Independent Board Member
Awards
1st place Diamond Prize winner 2018
1ST PLACE WINNER $200K COMPETITION 2018,
"PATIENT-PHYSICIAN RELATIONS" WINNER
RICE BROWN SCHOOL OF ENGINEERING TECH INNOVATION PRIZE
"Innovatech" award
"impacto salud" award
Our Origin Story
Leuko is a company that spun out from the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium. The founders were research fellows in a biomedical technology innovation initiative who felt compelled to solve a big unmet medical need for cancer patients undergoing chemotherapy.
You can read more about our story at the MIT Innovation Initiative
